Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Mar 28, 2025, 4:00 PM
1.350
+0.030 (2.25%)
After-hours: Mar 28, 2025, 5:59 PM EDT
Company Description
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States.
Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex.
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Mark Manfredi |
Contact Details
Address: 645 Summer Street, Suite 101 Boston, Massachusetts 02210 United States | |
| Phone | 857 273 8343 |
| Website | ikenaoncology.com |
Stock Details
| Ticker Symbol | IKNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G108 |
| ISIN Number | US45175G1085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development and Treasurer |
| Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy and Communication |
| Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Bob Lally | Senior Vice President of Finance and Operations |
| David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
| Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | S-4 | Filing |
| Mar 6, 2025 | ARS | Filing |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | 425 | Filing |
| Dec 31, 2024 | SCHEDULE 13G | Filing |
| Dec 23, 2024 | 425 | Filing |